Cargando…

mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma

BACKGROUND: Systemic therapy has proven only marginal effects in hepatocellular carcinoma (HCC) so far. The aim of this study was to evaluate the effect of targeting fibroblast growth factor receptor (FGFR) on tumour and stromal cells in HCC models. METHODS: Human and murine HCC cells, endothelial c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheller, T, Hellerbrand, C, Moser, C, Schmidt, K, Kroemer, A, Brunner, S M, Schlitt, H J, Geissler, E K, Lang, S A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453944/ https://www.ncbi.nlm.nih.gov/pubmed/25688743 http://dx.doi.org/10.1038/bjc.2014.638

Ejemplares similares

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
por: Schayowitz, A, et al.
Publicado: (2010)

Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer
por: Zuo, M, et al.
Publicado: (2015)

Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
por: Makhov, P, et al.
Publicado: (2014)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
por: Jimeno, A, et al.
Publicado: (2007)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
por: Presneau, N, et al.
Publicado: (2009)

SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway
por: Liu, Weiwei, et al.
Publicado: (2017)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
por: Campbell, L, et al.
Publicado: (2008)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
por: Cao, P, et al.
Publicado: (2009)

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
por: García-Martínez, J M, et al.
Publicado: (2011)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells
por: Sudhagar, S, et al.
Publicado: (2011)

Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration
por: Sonvilla, G, et al.
Publicado: (2010)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
por: Broutin, Sophie, et al.
Publicado: (2016)

The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence
por: Sun, C K, et al.
Publicado: (2007)

Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts
por: Chiu, M, et al.
Publicado: (2014)

A methoxy derivative of resveratrol analogue selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts
por: Gosslau, A, et al.
Publicado: (2005)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells
por: Fontijn, D, et al.
Publicado: (2006)

Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells
por: Siveen, K S, et al.
Publicado: (2014)

PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice
por: Shen, B, et al.
Publicado: (2012)

Elevated expression of artemis in human fibroblast cells is associated with cellular radiosensitivity and increased apoptosis
por: Ulus-Senguloglu, G, et al.
Publicado: (2012)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields
por: Costa, F P, et al.
Publicado: (2011)

Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells
por: Tomimaru, Y, et al.
Publicado: (2010)

PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death
por: Hotfilder, M, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_1122tikmr8frnr82ek3fuja86q